Back to Newsroom

NIH Awards $1.7 Million Grant for Celdara Medical and Pulmatrix to Develop an Inhaled Biologic Treatment for Idiopathic Pulmonary Fibrosis

LEBANON, N.H., and LEXINGTON, Mass., Oct. 1, 2015 /PRNewswire/ — Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute  of the National Institutes of Health has awarded a three-year, $1.7 million Fast Track Small Business Innovation Research grant to fund the companies’ development of an inhaled biologic to treat idiopathic pulmonary fibrosis.  The biologic, CM-YJH01, targets a novel pathway intended to prevent epithelial cell death. Celdara Medical will combine CM-YJH01 with Pulmatrix’s novel iSPERSE™ dry powder technology, which facilitates efficient administration of macromolecules to the lungs. The goal is to design an inhaled treatment candidate that addresses progressive scar tissue build up (fibrosis) directly at the affected disease site of patients’ lungs.

Click here to read more